ALLMedicine™ Pleural Effusions Center
Research & Reviews 399 results
https://doi.org/10.1186/s13019-021-01475-1 10.1186/s40425-019-0590-4 10.1164/ajrccm.162.5.ats8-00 10.1378/chest.116.1.266 10.21037/jtd.2017.06.52 10.1378/chest.12-1087 10.1183/13993003.00349-2018 10.1097/JTO.0b013e3181e95cb8 10.1111/1759-7714.12354 10.21037/jtd.2020.01.13 10.1371/journal.pone.0087060 10.1186/2049-3258-72-39 10.1111/j.1440-1843.2005.00763.x 10.1007/s00464-005-0534-6 10.1186/1749-8090-5-27 10.1001/jama.2019.19997 10.1016/s1010-7940(01)01130-7 10.1016/0003-4975(90)90730-t 10.1378/chest.119.3.801 10.1164/ajrccm.162.4.2002030 10.1378/chest.127.3.909 10.1378/chest.129.2.356 10.1136/thoraxjnl-2012-203043 10.1378/chest.09-2020 10.3892/or.2011.1559 10.1016/j.athoracsur.2012.01.103 10.2169/internalmedicine.52.9281 10.1016/S0140-6736(07)60708-9 10.1378/chest.128.3.1431 10.1510/icvts.2005.118018 10.1186/1749-8090-6-87 10.1046/j.1445-2197.2003.02616.x 10.1016/j.ejcts.2010.09.005 10.1378/chest.10-1868 10.1016/j.ejcts.2006.10.002 10.1378/chest.110.6.1387 10.1016/S0003-4975(96)00808-9 10.5507/bp.2012.095 10.1111/resp.12328 10.1164/rccm.200311-1579OC 10.1159/000342042 10.1016/j.rmed.2008.07.021 10.1016/s0002-9610(99)00075-6 10.1046/j.1440-1843.2001.00327.x 10.1016/S0022-5223(19)37535-X 10.1111/resp.13192 10.1001/jama.2012.5535 10.1590/s1807-59322007000500015 10.1378/chest.124.6.2229 10.1590/s1806-37132010000600014
Journal of Cardiothoracic Surgery; Zhang W, Zhao YL et. al.
May 5th, 2021 - Talc pleurodesis is an effective treatment for malignant pleural effusions (MPEs). This study was designed to estimate complication rates of thoracoscopic talc insufflation. Literature search was conducted in electronic databases and studies were ...
https://doi.org/10.1371/journal.pone.0250628
PloS One; Popowicz N, Cheah HM et. al.
Apr 26th, 2021 - Predicting survival of patients with malignant pleural effusions (MPEs) is notoriously difficult. A robust prognostic marker can guide clinical decision making. The neutrophil-to-lymphocyte ratio (NLR) in blood has been shown to predict survival i...
https://doi.org/10.1016/j.chest.2021.03.059
Chest Molina S, Martinez-Zayas G et. al.
Apr 14th, 2021 - Evidence-based guidelines recommend management strategies for malignant pleural effusions (MPE) based on life expectancy. Existent risk-prediction rules do not provide precise individualized survival estimates. Can a newly developed continuous ris...
https://doi.org/10.1016/j.chest.2021.02.052
Chest Mishra EK, Muruganandan S et. al.
Mar 5th, 2021 - Patients with malignant pleural effusions (MPEs) experience breathlessness and poor survival. Breathlessness is associated with poor survival in other conditions. Is breathlessness, measured using a visual analog scale for dyspnea (VASD), associat...
https://doi.org/10.1016/j.cyto.2021.155469
Cytokine Kotsiou OS, Jagirdar RM et. al.
Feb 19th, 2021 - High mobility group box 1(HMGB1) protein operates as an alarmin with multiple roles in immunity and cell homeostasis. It is highly expressed in epithelial barrier sites and acts via the binding to the receptor for advanced glycation end products (...
Guidelines 1 results
https://doi.org/10.1183/13993003.00349-2018
The European Respiratory Journal; Bibby AC, Dorn P et. al.
Jul 28th, 2018 - Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE m...
Clinicaltrials.gov 401 results
https://doi.org/10.1186/s13019-021-01475-1 10.1186/s40425-019-0590-4 10.1164/ajrccm.162.5.ats8-00 10.1378/chest.116.1.266 10.21037/jtd.2017.06.52 10.1378/chest.12-1087 10.1183/13993003.00349-2018 10.1097/JTO.0b013e3181e95cb8 10.1111/1759-7714.12354 10.21037/jtd.2020.01.13 10.1371/journal.pone.0087060 10.1186/2049-3258-72-39 10.1111/j.1440-1843.2005.00763.x 10.1007/s00464-005-0534-6 10.1186/1749-8090-5-27 10.1001/jama.2019.19997 10.1016/s1010-7940(01)01130-7 10.1016/0003-4975(90)90730-t 10.1378/chest.119.3.801 10.1164/ajrccm.162.4.2002030 10.1378/chest.127.3.909 10.1378/chest.129.2.356 10.1136/thoraxjnl-2012-203043 10.1378/chest.09-2020 10.3892/or.2011.1559 10.1016/j.athoracsur.2012.01.103 10.2169/internalmedicine.52.9281 10.1016/S0140-6736(07)60708-9 10.1378/chest.128.3.1431 10.1510/icvts.2005.118018 10.1186/1749-8090-6-87 10.1046/j.1445-2197.2003.02616.x 10.1016/j.ejcts.2010.09.005 10.1378/chest.10-1868 10.1016/j.ejcts.2006.10.002 10.1378/chest.110.6.1387 10.1016/S0003-4975(96)00808-9 10.5507/bp.2012.095 10.1111/resp.12328 10.1164/rccm.200311-1579OC 10.1159/000342042 10.1016/j.rmed.2008.07.021 10.1016/s0002-9610(99)00075-6 10.1046/j.1440-1843.2001.00327.x 10.1016/S0022-5223(19)37535-X 10.1111/resp.13192 10.1001/jama.2012.5535 10.1590/s1807-59322007000500015 10.1378/chest.124.6.2229 10.1590/s1806-37132010000600014
Journal of Cardiothoracic Surgery; Zhang W, Zhao YL et. al.
May 5th, 2021 - Talc pleurodesis is an effective treatment for malignant pleural effusions (MPEs). This study was designed to estimate complication rates of thoracoscopic talc insufflation. Literature search was conducted in electronic databases and studies were ...
https://doi.org/10.1371/journal.pone.0250628
PloS One; Popowicz N, Cheah HM et. al.
Apr 26th, 2021 - Predicting survival of patients with malignant pleural effusions (MPEs) is notoriously difficult. A robust prognostic marker can guide clinical decision making. The neutrophil-to-lymphocyte ratio (NLR) in blood has been shown to predict survival i...
https://doi.org/10.1016/j.chest.2021.03.059
Chest Molina S, Martinez-Zayas G et. al.
Apr 14th, 2021 - Evidence-based guidelines recommend management strategies for malignant pleural effusions (MPE) based on life expectancy. Existent risk-prediction rules do not provide precise individualized survival estimates. Can a newly developed continuous ris...
https://doi.org/10.1016/j.chest.2021.02.052
Chest Mishra EK, Muruganandan S et. al.
Mar 5th, 2021 - Patients with malignant pleural effusions (MPEs) experience breathlessness and poor survival. Breathlessness is associated with poor survival in other conditions. Is breathlessness, measured using a visual analog scale for dyspnea (VASD), associat...
https://doi.org/10.1016/j.cyto.2021.155469
Cytokine Kotsiou OS, Jagirdar RM et. al.
Feb 19th, 2021 - High mobility group box 1(HMGB1) protein operates as an alarmin with multiple roles in immunity and cell homeostasis. It is highly expressed in epithelial barrier sites and acts via the binding to the receptor for advanced glycation end products (...
News 2 results
https://www.mdedge.com/chestphysician/article/214641/society-news/cardiovascular-medicine-and-surgery-network/page/0/1?channel=28399
Jan 17th, 2020 - Clinical pulmonary medicine Definitive pleural interventions in malignant pleural effusions Malignant pleural effusions (MPEs) contribute significantly to symptom burden, and an emphasis on patient-centered outcomes prioritizes palliation of sympt.
https://www.medpagetoday.com/pulmonology/lungcancer/15660
Aug 24th, 2009 - Action Points Explain to patients that measuring mesothelin, a glycoprotein released by mesothelioma cells into pleural fluid, may help improve physicians' ability to determine whether a patient has mesothelioma. Pleural-fluid mesothelin outperfor...
